Designing a light-activated recombinant alpha hemolysin for colorectal cancer targeting

Siamak Alizadeh ^1,2, Abolfazl Barzegari ², Abolghasem Esmaeili ¹ * , Yadollah Omidi ^2,3 *

Cited by CrossRef: 9

1- Akbarzadeh-Khiavi M, Farzi-Khajeh H, Somi M, Safary A, Barar J, Ansari R, Omidi Y. Eradication of KRAS mutant colorectal adenocarcinoma by PEGylated gold nanoparticles-cetuximab conjugates through ROS-dependent apoptosis. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2022;653:129890 [Crossref]

2- Wu S, He L, Yang L, Li X, Wang J, Ren M, Gao Y, Chen Y, Wei H, Zhang M, Gou M. Neutral Nanocomplex Delivers Plasmid Encoding α‐Hemolysin for Uveal Melanoma Treatment. Advanced Therapeutics. 2024;7(10) [Crossref]

3- Cho K, Heo J, Han J, Hong H, Jeon H, Hwang H, Hong C, Kim D, Han J, Baek K. Industrial Applications of Dinoflagellate Phycotoxins Based on Their Modes of Action: A Review. Toxins. 2020;12(12):805 [Crossref]

4- Wei Y, Sandhu E, Yang X, Yang J, Ren Y, Gao X. Bidirectional Functional Effects of Staphylococcus on Carcinogenesis. Microorganisms. 2022;10(12):2353 [Crossref]

5- Tao C, Miao X, Yan J, Xiao X, Wu R, Cao Q, Wang Z, Lv R, Ge T, Liu J. Hypoxia-targeted and spatial-selective tumor suppression by near infrared nanoantenna sensitized engineered bacteria. Acta Biomaterialia. 2023;170:442 [Crossref]

6- Ohlendorf R, Möglich A. Light-regulated gene expression in Bacteria: Fundamentals, advances, and perspectives. Front Bioeng Biotechnol. 2022;10 [Crossref]

7- Chen H, Lei P, Ji H, Yang Q, Peng B, Ma J, Fang Y, Qu L, Li H, Wu W, Jin L, Sun D. Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies. Materials Today Bio. 2023;18:100543 [Crossref]

8- Alizadeh S, Esmaeili A, Barar J, Omidi Y. Optogenetics: A new tool for cancer investigation and treatment. Bioimpacts. 2022;12(4):295 [Crossref]

9- Liu C, Wolf M, Ortego R, Grencewicz D, Sadler T, Eng C. Characterization of immunomodulating agents from Staphylococcus aureus for priming immunotherapy in triple-negative breast cancers. Sci Rep. 2024;14(1) [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons